
Conference Coverage
Latest Content

Repricing Fairly: Balancing MFN and Domestic Reforms

Olomorasib Showed Promising Antitumor Activity in NSCLC

Immigrant Children Face Health Care Barriers as Coverage Policies Tighten

Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD

Long-Term Adalimumab Improves Work, Life Quality in Psoriasis

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

McKesson's report highlights key trends in community oncology, emphasizing patient-centered care, precision medicine, and the need for innovative clinical trials.

FDA has granted sonrotoclax priority review for relapsed mantle cell lymphoma, showcasing promising trial results.

Screening among 45- to 49-year-olds rose nearly 10-fold in hospitals after US guideline updates, but disparities persist.

Within the same physician groups, 2-sided risk in Medicare Advantage (MA) was associated with higher quality and lower utilization for dually eligible beneficiaries compared with fee-for-service MA and traditional Medicare.

From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care
Experts explore advancements in telehealth and precision medicine, addressing cancer care gaps for rural and underserved populations in oncology.

New research reveals that total social media use does not significantly impact adolescents' body image concerns, challenging previous assumptions.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia.

Medicare Advantage beneficiaries with mental health diagnoses see more nurse practitioners and fewer internal medicine and emergency medicine specialists after switching to traditional Medicare.

Global chronic lymphocytic leukemia incidence and mortality is declining, but the disease’s prevalence has increased modestly.

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.


























































